ANI Pharmaceuticals to Discuss First Quarter 2026 Financial Results on May 8, 2026, at 8:00 a.m. ET

ANI Pharmaceuticals (Nasdaq: ANIP) will release its first quarter 2026 financial results on Friday, May 8, 2026, prior to market open.

Rhea-AI Summary

ANI Pharmaceuticals (Nasdaq: ANIP) will release its first quarter 2026 financial results on Friday, May 8, 2026, prior to market open.

A webcast and conference call with CEO Nikhil Lalwani, CFO Stephen P. Carey, and Head of Rare Disease Chris Mutz will discuss the results; a replay will remain accessible for up to one year. Webcast links are on the Investors > Events & Presentations page.

Argus Apr 24 session

+0.74% close to close Open Argus

Details

News Market Reaction – ANIP

In the Apr 24 session, ANIP gained 0.74%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement sets the timetable for ANI’s Q1 2026 earnings release on May 8, 2026 and the accom...

Analysis

This announcement sets the timetable for ANI’s Q1 2026 earnings release on May 8, 2026 and the accompanying 8:00 a.m. ET webcast. In recent quarters, ANI has reported record revenues and repeatedly raised or reaffirmed guidance, so investors may compare upcoming results against prior record 2025 quarters and the >$1B 2026 revenue and $275M–$290M EBITDA targets. Key watchpoints will be revenue mix and progress in Rare Disease and Generics.

Key Figures

Earnings release date: May 8, 2026 Conference call time: 8:00 a.m. ET Replay availability: Up to one year

Earnings release date

May 8, 2026

Q1 2026 financial results release before market open

Conference call time

8:00 a.m. ET

Scheduled webcast and conference call to discuss Q1 2026 results

Replay availability

Up to one year

Webcast replay access period on company’s investor site

Previous Earnings Reports

5 past events · Latest: Feb 27

Same Type 5 events

1. Feb 27

   Earnings results

   24h Move

   -4.2%

   Record Q4 and 2025 results with reaffirmed 2026 revenue and EBITDA guidance.

2. Feb 13

   Earnings call notice

   24h Move

   +0.9%

   Announcement of Q4 and full-year 2025 results release and conference call.

3. Nov 07

   Earnings results

   24h Move

   +0.2%

   Record Q3 2025 results and raised 2025 revenue and EBITDA guidance.

4. Oct 24

   Earnings call notice

   24h Move

   -0.7%

   Scheduling of Q3 2025 results release and investor conference call.

5. Aug 08

   Earnings results

   24h Move

   +18.1%

   Record Q2 2025 results and raised full-year 2025 revenue and EBITDA guidance.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

PRINCETON, N.J., April 24, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that the Company will release its first quarter 2026 financial results on Friday, May 8, 2026, prior to the market open.

Nikhil Lalwani, President and Chief Executive Officer, Stephen P. Carey, Senior Vice President, Finance, and Chief Financial Officer, and Chris Mutz, Head of Rare Disease will host a webcast and conference call to discuss the results.

To view the webcast, please click here. Links to access the webcast and conference call will also be available on the “Events & Presentations” page of the Company’s website at https://www.anipharmaceuticals.com, under the “Investors” section. A replay of the event will remain accessible for up to one year.

About ANI
ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) is a diversified biopharmaceutical company committed to its mission of “Serving Patients, Improving Lives" by developing, manufacturing, and commercializing innovative and high-quality therapeutics. The Company is focused on delivering sustainable growth through its Rare Disease business, which markets novel products in the areas of ophthalmology, rheumatology, nephrology, neurology, and pulmonology; its Generics business, which leverages R&D expertise, operational excellence, and U.S.-based manufacturing; and its Brands business. For more information, visit https://www.anipharmaceuticals.com.

Investor Relations:
Courtney Mogerley, Argot Partners
T: 646-368-8014
E: ani@argotpartners.com

Media Relations:
Argot Partners
T: 212-600-1494
E: ani@argotpartners.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When will ANI Pharmaceuticals (ANIP) release Q1 2026 results?

ANI will release its Q1 2026 financial results on May 8, 2026, before market open. According to the company, the release precedes a webcast and conference call where management will discuss the quarter and answer investor questions.

How can investors access the ANIP Q1 2026 webcast and conference call?

Investors can access the webcast via the company’s investor site under Events & Presentations. According to the company, links to the live webcast and conference call will be posted on the Investors page before the event.

Who will present on the ANIP Q1 2026 earnings call?

Presenters include CEO Nikhil Lalwani, CFO Stephen P. Carey, and Head of Rare Disease Chris Mutz. According to the company, these executives will host the webcast and conference call to discuss financial results and related business updates.

Will a replay of the ANIP May 8, 2026 webcast be available?

Yes. A replay of the webcast and conference call will remain available for up to one year. According to the company, the replay will be accessible from the Investors > Events & Presentations page on the company website.

What topics will ANIP cover during the May 8, 2026 webcast for ANIP shareholders?

The webcast will discuss the company’s first quarter 2026 financial results and related business matters. According to the company, management will review the quarter’s results and take investor questions during the conference call portion.